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Objectives: We performed a phase I trial to assess the safety and tolerance of a Lactobacillus vaginal suppository for prevention of
recurrent UTI. Methods: Premenopausal women with a history of recurrent UTI were randomized to use L. crispatus CTV-05 or
placebo vaginal suppositories daily for ﬁve days. Results: 30 women were randomized (15 to L. crispatus CTV-05). No severe ad-
verseeventsoccurred.Mildtomoderatevaginaldischargeandgenitalirritationwerereportedbywomeninbothstudyarms.Seven
women randomized to L. crispatus CTV-05developed pyuria without associated symptoms. Most women had high concentrations
of vaginal H202-producing lactobacilli before randomization. L. crispatus, L. jensenii,a n dL. gasseri were the most common Lacto-
bacillus species identiﬁed, with stable prevalence over time. Conclusions: L. crispatus CTV-05 can be given as a vaginal suppository
with minimal sideeﬀects to healthy women with a history of recurrent UTI. Mild inﬂammation of the urinary tract was noted in
some women.
Copyright © 2007 Christopher A. Czaja et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1. INTRODUCTION
Urinary tract infections (UTIs) aﬀect millions of women
each year, with an annual societal cost of billions of dollars
[1]. Importantly, more than one quarter of women with a
UTI will have a recurrent infection within six months [2].
TherearefewestablishedoptionsforpreventionofUTIother
than the use of prophylactic antibiotics [3]. However, resis-
tanceto commonlyused antibiotics is increasing among bac-
terial cystitis isolates [4]. Therefore, eﬀective nonantibiotic
methods of prevention are needed. One potential alternative
may be a lactobacillus probiotic.
A growing body of evidence suggests that vaginal H202-
producing lactobacilli may have a protective eﬀect against
urogenital infections, including UTI [5–11]. It is hypothe-
sized that lactobacilli prevent uropathogen colonization of
the vagina, a necessary step in ascending infection of the
bladder. Several clinical trials have demonstrated that certain
Lactobacillus species, mainly L. rhamnosus and L. fermentum,
can be given orally or vaginally with resulting colonization of
thevagina,reductioninvaginalcoliformcounts,andevenre-
ductioninUTIrecurrence[12–18].Speciﬁcstrainswerecho-
sen for their abilities to produce H202, adhere to uroepithe-
lial cells, interfere with uropathogen attachment and growth,
and persist in the vagina [18, 19]. The most frequently ex-
isting vaginal Lactobacillus species, L. crispatus [20, 21], also
produces H202 and possesses the adherence and inhibitory
qualities essential for a good probiotic candidate [22, 23].
L. crispatus strain CTV-05 has been developed as a vagi-
nal suppository (LACTIN-V) for the prevention of recur-
rent UTI in women. L. crispatus CTV-05 is highly adherent
to vaginal epithelial cells [24], and when given as a suppos-
itory can colonize the vagina [25]. Furthermore, L. crispa-
tus CTV-05 has been reported to have a speciﬁc DNA ﬁn-
gerprint that distinguishes it from endogenous vaginal lacto-
bacilli [25]. To further evaluate the safety of this new formu-
lation of L. crispatus CTV-05 and its eﬀect on the vaginal mi-
crobial ﬂora, we conducted a phase I, randomized, double-
blind, placebo-controlled trial of vaginal L. crispatus CTV-05
in premenopausal women with a history of recurrent UTI.
2. SUBJECTS AND METHODS
Participants
We recruited premenopausal women aged 18–35 years with
a history of three or more uncomplicated UTIs diagnosed
in the past year, or two uncomplicated UTIs diagnosed in2 Infectious Diseases in Obstetrics and Gynecology
the past six months, from (student health center, University
of Washington, Wash, USA.) Additional eligibility require-
ments included regular menstrual cycles or amenorrhea for
at least six months secondary to use of a hormonal contra-
ceptive, a normal Pap smear documented in the last year or
at the baseline clinic visit, abstinence from sexual activity
or participation in a mutually monogamous sexual relation-
ship, use of birth control, agreement not to use other intrav-
aginal products, agreement not to have sexual intercourse or
use tampons between the baseline and ﬁrst follow-up visit,
and capability to understand English and provide informed
consent. Exclusion criteria included history of urologic ab-
normality,recenturologicsurgeryorurinarycatheterization,
history of complicated pyelonephritis or renal calculi, hys-
terectomy,recentsexuallytransmittedinfection(STI)orbac-
terial vaginosis, risk factors for STI and HIV, history of re-
current genital herpes, menses anticipated within ten days,
pregnancy, lactation, recent antibiotic or antifungal use, di-
abetes or other immunocompromised state, drug or alcohol
abuse, use of the (NuvaRing), prior use of the study drug or
allergy to any of its components, and abnormal initial pelvic
examination. The study was approved by (Institutional Re-
view Board (IRB), University of Washington, Wash, USA.)
Studydesign
Subjects were randomized in a double-blinded fashion to L.
crispatus CTV-05 at a dose of 5 × 108 colony forming units
(cfu) or placebo vaginal suppository to be inserted daily for
ﬁve days. L.crispatusCTV-05andplacebosuppositorieswere
similar in appearance and consisted of a preservation matrix
and maltodextran. Both were prepackaged by the manufac-
turer (Osel, Inc., Palo Alto, Calif, USA) according to a ran-
domization schedule and supplied to the study site sequen-
tially labeled with a subject number.
Subjects were seen at three clinic visits over a period
of one month. At the ﬁrst (baseline) visit, eligible subjects
provided informed consent before undergoing a structured
medical and gynecologic history and physical examination.
They provided urine, vaginal, and cervical specimens. Sub-
jects inserted the ﬁrst dose of study drug in the clinic and
were instructed to record any symptoms occurring during
theﬁrstweekofstudyonaprepareddiarycard.Subjectswere
seen in follow-up 6–8 days (1-week) visit and 26–34 days (4-
week) visit after enrollment. During these visits, new symp-
toms, new urogenital infections, and any changes in clinical
history were recorded. Follow-up visits were otherwise sim-
ilar to the baseline visit. Finally, subjects were contacted by
telephone six months after enrollment to assess symptoms,
pregnancy, new diagnoses, or major medical events.
Laboratory testing included urine dipstick testing, uri-
nalysis, urine culture, vaginal ﬂuid wet preparation slides,
gram stains, and culture for facultative isolates and Lac-
tobacillus species at all visits. Repetitive element sequence-
based polymerase chain reaction (rep-PCR) for L. crispatus
CTV-05 was performed on three lactobacillus colonies from
culture at each visit [25]. Urine pregnancy testing was per-
formedatthebaselineand4-weekvisits.TestingforNeisseria
gonorrhoeae and Chlamydia trachomatis by DNA ampliﬁca-
tion was done at the baseline visit.
A sample size of 30 was chosen to evaluate the primary
outcome of safety as assessed through self-reported symp-
toms, physical exam ﬁndings, and laboratory studies. Sec-
ondary outcomes included shifts in the vaginal ﬂora assessed
by vaginal culture and vaginal colonization with L. crispatus
CTV-05 assessed by rep-PCR. The Fisher exact test was used
to test statistical signiﬁcance.
3. RESULTS
Thirty women were randomized (15 to L. crispatus CTV-05).
All subjects took the ﬁve planned doses of study drug. Two
women randomized to L. crispatus CTV-05 completed treat-
ment over six days, and one woman randomized to placebo
used six suppositories over six days. All women remained on
study through the 4-week visit (Figure 1).
Baselinecharacteristicsofsubjectsweresimilarinthetwo
treatment groups (Table 1). The majority of women were
young, white, healthy, university students in their 20s. The
median number of UTIs in the last year was three. Screening
tests for pregnancy and STI were negative for all subjects.
Safety
There were no severe adverse events. Mild to moderate ad-
verse events were relatively common, however. Of those felt
by the investigators to be related to study drug use, abnor-
mal vaginal discharge was the most frequently occurring,
followed by external genital irritation and vaginal candidi-
asis (Table 2). These adverse events occurred with similar or
greater frequency in women randomized to placebo as com-
pared to women randomized to L. crispatus CTV-05. Three
women reporting vaginal candidiasis also reported multiple
prior episodes in the preceding 12 months. Two women ran-
domized to L. crispatus CTV-05 reported episodes of cystitis
during the study.
All subjects completed a diary card of symptoms that oc-
curred during the period of study drug insertion. Recorded
symptoms generally conﬁrmed the reported adverse events
and were similar to symptoms reported at the 1-week clinic
visit (below). These symptoms occurred with similar fre-
quency in each treatment arm.
Abnormal vaginal discharge was the symptom most fre-
quently reported by subjects at clinic visits following study
drug use (Figure 2). While no women reported abnormal
vaginal discharge at baseline, six randomized to L. crispatus
CTV-05 and ﬁve randomized to placebo reported abnormal
vaginal discharge at the 1-week visit. Abnormal discharge
was less frequently reported at the 4-week visit. External gen-
ital or vaginal irritation was also reported by six women in
each treatment arm at follow-up visits. Vaginal odor was re-
ported at the 1-week visit by one woman randomized to L.
crispatusCTV-05, and at the 4-week visit by two women ran-
domized to placebo. Dysuria was reported by one woman
randomized to L. crispatus CTV-05 at the 1-week visit and by
one woman randomized to placebo at the 1- and 4-week vis-
its. Headache, abdominal or pelvic cramps/abdominal pain,Christopher A. Czaja et al. 3
30 women randomized
Baseline visit
15 assigned to L. crispatus
CTV-05 × 5d a y s
15 assigned to placebo × 5d a y s
1-week visit
15 completed treatment and
diary (2 completed treatment
over 6 days)
15 completed treatment and
diary (1 completed 6 doses
over 6 days)
4-week visit 15 completed the study 15 completed the study
6-month
phone call
9 completed telephone
follow-up
10 completed telephone
follow-up
Figure 1: Randomization and followup of subjects.
Table 1: Baseline characteristics of study subjects.
CTV-05 (N = 15) Placebo (N = 15) All (N = 30)
Age (years)
Median 23 21 21.5
Range 18–35 19–32 18–35
UTI in the past 12 months (no.)
Median 3 3 3
Range 2–6 2–6 2–6
Race (no.)
White 13 12 25
Asian 2 2 4
Native American 0 1 1
Hispanic ethnicity (no.) 0 1 1
Marital status (no.)
Single 13 11 24
Partner > 4m o n t h s 1 2 3
Married 0 1 1
Divorced 1 1 2
Occupation (no.)
Student 11 10 21
Employed full-time 3 5 8
Unemployed 1 0 1
Major medical problem ever (no.) 1 1 2
Pregnant ever (no.) 2 1 3
Abnormal Pap ever (no.) 1 1 2
Antimicrobial use past 30 days (no.) 1 2 3
Sex in the past 30 days (no.) 11 13 24
CTV-05, L. crispatus CTV-05.4 Infectious Diseases in Obstetrics and Gynecology
Table 2: Adverse events related to study drug use.
CTV-05 (N = 15) Placebo (N = 15) P
Abnormal vaginal discharge 6 7 1.00
External genital irritation 1 5 .17
Vaginal Candidiasis 4 2 .65
Vaginal odor 1 0 1.00
Abdominal or pelvic cramps/abdominal pain 0 1 1.00
Dysuria 0 1 1.00
CTV-05, L. crispatus CTV-05.
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Figure 2: Symptoms reported by ≥2 women at clinic visits (P>. 05
forcomparisonofL.crispatusCTV-05toplaceboatallvisits).CTV-
05, L. crispatus CTV-05; DC, abnormal vaginal discharge; IRR, ex-
ternal genital or vaginal irritation; ODOR, vaginal odor; DYS, dy-
suria; HA, headache; APP, abdominal or pelvic pain/cramps; LBP,
low back pain.
andlowbackpainwerefrequentlyreportedatbaselineaswell
as at follow-up visits. There were no signiﬁcant diﬀerences in
reported symptoms at any visit between women in the two
treatment arms.
Physical exam ﬁndings were benign in both treatment
arms. External genital erythema was found at the 1- and
4-week visits in more women randomized to L. crispatus
CTV-05 than in women randomized to placebo (4 versus
1, P = .33). Moderate-to-profuse vaginal discharge was fre-
quently found in women from both treatment arms during
follow-up examinations (12 versus 8, P = 1.00), though this
ﬁndingwasalsooftenapparentatthebaselinevisit(6women
in each arm). One woman randomized to placebo had vagi-
nal erythema noted at 1 week. No cervical, urethral, uterine,
or adnexal abnormalities were noted.
Seven (47%) women randomized to L. crispatus CTV-
05 had nine episodes of pyuria with a urine white blood
cell count ≥8p e rm m 3 [26] (range 8–203) during a follow-
up clinic visit (Table 3). None of these women had pyuria
at baseline. In contrast, none of the women randomized to
placebo had pyuria at 1 or 4 weeks (P = .01). Pyuria was
positivelycorrelatedwithurineleukocyte-esterasetestresults
(Spearman r = 0.57, P<. 01). There were no signiﬁcant asso-
ciations with vaginal or urinary symptoms or exam ﬁndings.
Microbes isolated from the urine of women in the L. crispa-
tus CTV-05 arm with pyuria included mixed gram-positive
organisms (6), lactobacillus (3), E. coli (1), enterococcus (1),
group B streptococcus (1), and yeast (1). One subject had
a negative urine culture, and none had symptomatic infec-
tion. Lactobacillus and mixed gram-positive rods were iso-
lated at 103-104 cfu/ml from more women with pyuria (50%
and 75%) than without (19% and 46%, resp.) at the 1-week
visit (P = .22 for lactobacillus, P = .60 for mixed gram-
positive rods) but not at the 4-week visit. None of the other
isolated organisms was found at a signiﬁcantly increased fre-
quency in women randomized to L. crispatus CTV-05 versus
placebo or in women with pyuria compared to those without
pyuria at any visit. Two women randomized to L. crispatus
CTV-05 and one randomized to placebo had hematuria at
the 4-week visit (≥30 red blood cells per mm3).
Nine women in the L. crispatus CTV-05 arm and ten in
the placebo arm completed the six-month follow-up tele-
phone call. None reported pregnancy, and no major health
problems occurred. Four women in the L. crispatus CTV-
05 arm and one in the placebo arm reported one or more
episodes of cystitis.
Effectsonvaginalﬂora
28 of 30 women had vaginal colonization with H202-
producing lactobacilli at baseline and all follow-up visits
(Table 4).Twowomenrandomizedtoplacebohadnovaginal
H202-producing lactobacilli detected at any clinic visit. One
of these women had large quantities of Gardnerella and Bac-
teroides species morphotypes on gram stain. Cultures from
women with H202-producing lactobacilli yielded heavy (4+)
growth.
Vaginal cultures from ﬁve women in each treatment arm
yielded E. coli from one or more clinic visits. E. coli was iso-
lated from vaginal cultures taken at the 1- and 4-week vis-
its from 4 women randomized to L. crispatus CTV-05 and
from one women randomized to placebo (P = .33). No in-
verse association between vaginal colonization with H202-
producing lactobacilli and vaginal colonization with E. coli
was detected. Vaginal cultures frequently yielded Candida at
baseline as well as follow-up visits.Christopher A. Czaja et al. 5
Table 3: Subjects with pyuria∗ at follow-up clinic visits.
CTV-05 (N = 15) Placebo (N = 15) P
Baseline 0 2 .48
1-Week 4 0 .10
4-Week 5 0 .04
CTV-05, L. crispatus CTV-05.
∗Urine white blood cell count ≥8/mm3.
Table 4: Subjects with vaginal H2O2-producing Lactobacillus detected at follow-up clinic visits.
CTV-05 (N = 15) Placebo (N = 15∗)
SQ Count 0 1+ 2+ 3+ 4+ 0 1+ 2+ 3+ 4+
N u m b e r o f s u b j e c t s B a s e l i n e 0 0001 5 2 0201 1
1 - W e e k 0 0001 5 2 0011 2
4-Week 0 0 0 0 13∗∗ 2 0011 2
CTV-05, L. crispatus CTV-05; SQ, semiquantitative.
∗There were 2 women in the placebo group with no H2O2-producing lactobacilli detected at any visit. P = 0.48 at each visit for comparison of presence or
absence of H2O2-producing lactobacilli in the L. crispatus CTV-05 and Placebo groups.
∗∗All 15 subjects had positive vaginal cultures. Semi-quantitative data missing for 2.
Rep-PCR
Usingrep-PCR,L.crispatusCTV-05wasdetectedinthevagi-
nas of four women randomized to L.crispatus CTV-05 (three
womenateachclinicvisit).Threewomenhadapositiveassay
for L. crispatus CTV-05 detected at the baseline visit before
administration of the study drug. No women randomized to
placebo had a positive assay at any visit (P = .22 each visit).
We compared our rep-PCR results (Figure 3)t op r e v i -
ously published rep-PCR patterns [25] in order to identify
the bacterial species. At baseline, 80% of subjects had L.
crispatus, 37% had L. jensenii, 17% had L. gasseri, and 27%
had other Lactobacillus species detected in vaginal culture.
The following combinations of Lactobacillus species were
found: L. crispatus (27%), L. crispatus and L. jensenii (20%),
L. crispatus and L. gasseri (7%), L. crispatus and other Lacto-
bacillus species (13%), L. crispatus, L. jensenii,a n dL. gasseri
(3%), L. crispatus, L. jensenii, and other Lactobacillus species
(7%), L. crispatus, L. gasseri, and other Lactobacillus species
(3%), L. jensenii (7%), L. gasseri (3%), other Lactobacillus
species (3%), and no Lactobacillus (7%). The prevalences of
individual species were relatively stable over time (Figure 4).
There were no signiﬁcant diﬀerences in Lactobacillus species
prevalence between subjects in the two treatment arms with
the exception of L. gasseri at the 1-week visit (P = .02).
4. DISCUSSION
InphaseI,placebo-controlledtrial,useofaL.crispatusCTV-
05 vaginal suppository, for the prevention of recurrent UTI
was well tolerated with minimal side eﬀects. There were no
serious adverse events, and despite the occurrence of abnor-
mal vaginal discharge and external genital or vaginal irrita-
tion in several women, compliance was high. These mild to
moderatesymptomsappeartobesecondarytotheactofsup-
pository use or a reaction to the preservation matrix rather
than a consequence of L. crispatus CTV-05 as they occurred
withsimilarfrequencyamongwomenineachtreatmentarm.
Several women also reported vaginal candidiasis. However,
given the frequency of recurrent vaginal candidiasis experi-
enced by subjects prior to enrollment and the prevalence of
Candida in baseline vaginal cultures, the relationship of this
condition to study drug use is not compelling.
L. crispatus CTV-05 use was associated with pyuria (de-
tected by microscopy and urine leukocyte-esterase) in seven
women at either the 1- or 4-week visits (P = .04 at 4 weeks).
Pyuria was not associated with urogenital symptoms, exam
ﬁndings, or symptomatic UTI. While lactobacillus was not
isolated from the urine during every episode of pyuria, it is
possible that some lactobacilli were misclassiﬁed as mixed
gram-positive rods, as both were more frequently found in
women with pyuria than in women without. Our data sug-
gest that vaginal instillation of L. crispatus CTV-05 induces
a mild inﬂammatory response in the bladder or vaginal mu-
cosa of some subjects without causing prolonged urogeni-
tal infection. The importance of this phenomenon with re-
spect to safety or potential eﬃcacy is unclear. It is possible
that induction of an asymptomatic inﬂammatory response
by lactobacilli protects against uropathogen colonization of
the vagina or infection in the bladder [27].
Limited existing data from prior studies suggest that L.
crispatus therapy is safe. Women surveyed after participa-
tion in a clinical trial of a vaginal capsule formulation of L.
crispatus CTV-05 for treatment of bacterial vaginosis rarely
reported adverse eﬀects, and those reported were largely re-
lated to a perceived diﬀerence in vaginal discharge. Satisfac-
tion with the vaginal capsule was high [28]. No adverse ef-
fects were reported in a pilot study of L. crispatus CTV-05
given intravaginally to a small group of healthy women [25].
Nine women with a history of recurrent UTI reported no ad-
verse eﬀects when given L. crispatus strain GA198332 as a
vaginal suppository every other day for one year [29]. Stud-
ies of other probiotic strains of Lactobacillus have indicated
that they can be given to women safely with minimal or no6 Infectious Diseases in Obstetrics and Gynecology
MW C C J J G C J ∗ CGCJ
5090
4072
3054
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1636
Figure 3: Representative rep-PCR DNA ﬁngerprints from vaginal
lactobacillus isolates. MW, Molecular weight standard; C, L. crispa-
tus;J ,L. jensenii,G ,L. gasseri; ∗, L. crispatus CTV-05.
CTV-05 Placebo CTV-05 Placebo CTV-05 Placebo CTV-05 Placebo
L. crispatus L. jensenii L. gasseri Other
Lactobacillus
Treatment group and Lactobacillus species
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Figure 4: Prevalence of vaginal Lactobacillus species at clinic visits
(N = 15 for each treatment group. P>. 05 for comparison of L.
crispatus CTV-05 to placebo at all visits except for L. gasseri at 1-
week (P = .02)). CTV-05, L. crispatus CTV-05.
side eﬀects[12–18].To ourknowledge, pyuria resulting from
vaginal instillation of Lactobacillus has not been previously
reported, and should be evaluated further in future studies.
We did not see an eﬀect of L. crispatus CTV-05 use on
vaginal Lactobacillus growth. However, most study partici-
pants had heavy vaginal growth of H2O2-producing lacto-
bacilli at baseline, making detection of subsequent changes
diﬃcult. Data from a pilot study indicated that L. crispatus
CTV-05 did not displace other endogenous vaginal lacto-
bacilli. Vaginal colonization was most successful in women
lacking vaginal H2O2-producing lactobacilli at the outset,
suggesting that a lactobacillus probiotic may be most eﬀec-
tive at establishing vaginal colonization in women with ab-
normal ﬂora, such as those with bacterial vaginosis or recur-
rent UTI [25].
To our knowledge, our study represents the ﬁrst attempt
to use rep-PCR to identify the genetic ﬁngerprint of the pro-
biotic strain L. crispatus CTV-05 in a larger-scale clinical
study. Although none of the placebo recipients were colo-
nized with lactobacillus strains having the characteristic rep-
PCRpatternofL.crispatusCTV-05atanytime,threewomen
randomized to L. crispatus CTV-05 had at least one isolate
in their vaginal culture at baseline that bore the character-
istic ﬁngerprint. Therefore, colonization of the vagina fol-
lowing suppository administration was diﬃcult to demon-
strate. As there are no large-scale surveys of the prevalence
and distribution of lactobacilli bearing this ﬁngerprint, we
do not know whether the rep-PCR technique failed to dis-
tinguish L. crispatus CTV-05 from other genetically closely
related strains of L. crispatus naturally colonizing the vagina
at baseline, or whether the identical strain was prevalent in
our study population. Of note, subjects in our study had a
much higher prevalence of vaginal H2O2-producing lacto-
bacilli in baseline vaginal cultures than found in previous
studies [25]. By comparing our rep-PCR results to previ-
ouspublishedrep-PCRpatterns[25],wecharacterizedlacto-
bacillus isolates at the species level and found L. crispatus, L.
jensenii,a n dL. gasseri to be the most prevalent species, with
relatively stable prevalences over time. Our prevalence data
are consistent with what has been previously documented
[20, 21]. Additional tests are under way to compare quanti-
tative PCR results for L. crispatus in women before and after
the introduction of active suppositories or placebo.
Our study was not designed nor statistically powered to
evaluate the eﬀect of L. crispatus CTV-05 on the rate of UTI
recurrence. Therefore, it is diﬃcult to interpret the report of
cystitis in two women randomized to L. crispatus CTV-05.
Other small studies have suggested that use of vaginally ad-
ministered L. crispatus may be associated with a lower rate of
UTI recurrence [16, 29].
The major strengths of our study include the placebo-
controlled, randomized study design, excellent compliance,
and extensive and complete followup. Use of a study diary
provided ﬁner details of our subjects’ experiences that con-
ﬁrmed adverse events and symptoms reported from mem-
ory at clinic visits. Weaknesses that should be mentioned in-
clude the inability to accurately document vaginal coloniza-
tion with the probiotic strain, and the inherent lack of sta-
tistical power due to the small sample size typical of phase I
studies. We are currently conducting a phase II trial that will
have more power to clarify some of the issues raised in this
study.
In conclusion, L. crispatus CTV-05 is well tolerated when
given as a vaginal suppository to healthy women with a his-
tory of recurrent UTI. Mild to moderate side eﬀects related
to suppository use occur but do not aﬀect compliance. L.
crispatus CTV-05 may cause mild asymptomatic inﬂamma-
tion of the lower urinary tract. Timing of administration and
eﬃcacy in preventing recurrent cystitis should be evaluated
further in larger studies.
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